blank Quick help
blank Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability
Register Forum

2022.02.11

More...
blank News flashes

News Flashes

New version of the European Patent Register – SPC proceedings information in the Unitary Patent Register.

2024-07-24

More...
blank Related links

Release notes
European Patent Register Assistant
European Patent Register Resource Book
European Patent Register – pocket guide
FAQ - European Patent Register
FAQ - Register Alert
Federated Register (Flyer)
Global Dossier (Flyer)
Register events
Deep link coverage
Federated Register content
The Patent Information Tour
Fair use charter

Extract from the Register of European Patents

EP About this file: EP4178584

EP4178584 - HYDROXYAPATITE COMPOSITION COMPRISING ZOLEDRONIC ACID AND DOXORUBICIN FOR TREATING CANCER [Right-click to bookmark this link]
Former [2023/20]NOVEL TREATMENT REGIMEN OF CANCER
[2023/36]
StatusNo opposition filed within time limit
Status updated on  30.08.2024
Database last updated on 02.09.2024
FormerThe patent has been granted
Status updated on  22.09.2023
FormerGrant of patent is intended
Status updated on  21.08.2023
FormerRequest for examination was made
Status updated on  14.04.2023
FormerThe international publication has been made
Status updated on  16.04.2022
Formerunknown
Status updated on  02.11.2021
Most recent event   Tooltip30.08.2024No opposition filed within time limitpublished on 02.10.2024 [2024/40]
Applicant(s)For all designated states
Moroxite T AB
Kung Oscars väg 11c
222 35 Lund / SE
[2023/38]
Former [2023/20]For all designated states
Moroxite AB
Brobyggargatan 4
298 31 Tollarp / SE
Inventor(s)01 / LIDGREN, Lars
298 31 TOLLARP / SE
02 / TÄGIL, Magnus
298 31 TOLLARP / SE
03 / RAINA, Deepak
298 31 TOLLARP / SE
04 / YANG, Liu
298 31 TOLLARP / SE
 [2023/20]
Representative(s)Zacco Sweden AB
P.O. Box 5581
Löjtnantsgatan 21
114 85 Stockholm / SE
[2023/20]
Application number, filing date21793863.805.10.2021
[2023/20]
WO2021EP77420
Priority number, dateSE2020005117005.10.2020         Original published format: SE 2051170
[2023/20]
Filing languageEN
Procedural languageEN
PublicationType: A1 Application with search report
No.:WO2022073990
Date:14.04.2022
Language:EN
[2022/15]
Type: A1 Application with search report 
No.:EP4178584
Date:17.05.2023
Language:EN
The application published by WIPO in one of the EPO official languages on 14.04.2022 takes the place of the publication of the European patent application.
[2023/20]
Type: B1 Patent specification 
No.:EP4178584
Date:25.10.2023
Language:EN
[2023/43]
Search report(s)International search report - published on:EP14.04.2022
ClassificationIPC:A61K31/704, A61K31/675, A61P35/00, A61K9/14, A61K45/06, A61K9/00
[2023/36]
CPC:
A61P35/00 (EP,US); A61K9/143 (EP,US); A61K31/675 (EP,US);
A61K31/704 (EP,US); A61K45/06 (EP); A61K9/0019 (EP)
C-Set:
A61K31/675, A61K2300/00 (EP);
A61K31/704, A61K2300/00 (EP)
Former IPC [2023/20]A61K31/704, A61K31/675, A61P35/00, A61K9/14, A61K45/06
Designated contracting statesAL,   AT,   BE,   BG,   CH,   CY,   CZ,   DE,   DK,   EE,   ES,   FI,   FR,   GB,   GR,   HR,   HU,   IE,   IS,   IT,   LI,   LT,   LU,   LV,   MC,   MK,   MT,   NL,   NO,   PL,   PT,   RO,   RS,   SE,   SI,   SK,   SM,   TR [2023/20]  
TitleGerman:HYDROXYAPATIT-ZUSAMMENSETZUNG MIT ZOLEDRONSÄURE UND DOXORUBICIN ZUR BEHANDLUNG VON KREBS[2023/36]
English:HYDROXYAPATITE COMPOSITION COMPRISING ZOLEDRONIC ACID AND DOXORUBICIN FOR TREATING CANCER[2023/36]
French:COMPOSITION D'HYDROXYAPATITE COMPRENANT DE L'ACIDE ZOLÉDRONIQUE ET DE LA DOXORUBICINE POUR LE TRAITEMENT DU CANCER[2023/36]
Former [2023/20]NEUARTIGES BEHANDLUNGSSCHEMA FÜR KREBS
Former [2023/20]NOVEL TREATMENT REGIMEN OF CANCER
Former [2023/20]NOUVEAU RÉGIME DE TRAITEMENT DU CANCER
Entry into regional phase09.02.2023National basic fee paid 
09.02.2023Designation fee(s) paid 
09.02.2023Examination fee paid 
Examination procedure19.07.2022Request for preliminary examination filed
International Preliminary Examining Authority: EP
09.02.2023Amendment by applicant (claims and/or description)
09.02.2023Examination requested  [2023/20]
09.02.2023Date on which the examining division has become responsible
22.08.2023Communication of intention to grant the patent
11.09.2023Fee for grant paid
11.09.2023Fee for publishing/printing paid
11.09.2023Receipt of the translation of the claim(s)
Opposition(s)26.07.2024No opposition filed within time limit [2024/40]
Fees paidRenewal fee
18.09.2023Renewal fee patent year 03
Opt-out from the exclusive  Tooltip
competence of the Unified
Patent Court		 See the Register of the Unified Patent Court for opt-out data
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Lapses during opposition  TooltipCZ25.10.2023
HR25.10.2023
PL25.10.2023
RO25.10.2023
RS25.10.2023
SK25.10.2023
SM25.10.2023
NO25.01.2024
GR26.01.2024
IS25.02.2024
[2024/36]
Former [2024/35]CZ25.10.2023
HR25.10.2023
PL25.10.2023
RO25.10.2023
RS25.10.2023
SM25.10.2023
NO25.01.2024
GR26.01.2024
IS25.02.2024
Former [2024/33]HR25.10.2023
PL25.10.2023
RS25.10.2023
SM25.10.2023
NO25.01.2024
GR26.01.2024
IS25.02.2024
Former [2024/27]HR25.10.2023
PL25.10.2023
RS25.10.2023
NO25.01.2024
GR26.01.2024
IS25.02.2024
Former [2024/20]GR26.01.2024
IS25.02.2024
Cited inInternational search[Y]US2009215729  (JOHNSON ERIN M [US], et al) [Y] 1-28 * figures 1-9; claims 1-20 * * paragraphs [0012] , [0067] , [0082] , [0 89] * * examples 1-3 *;
 [XYI]WO2013008240  (YISSUM RES DEV CO [IL], et al) [X] 1,2,4-7,12-14,18,19,22,23,26,28 * examples 1-4; claims 1-73 * * page 20, paragraph 4 * [Y] 1-28 [I] 8-11,20,24,25,27;
 [XYI]  - PIGNATELLO ROSARIO ET AL, "Synthesis and Biological Evaluation of a New Polymeric Conjugate and Nanocarrier with Osteotropic Properties", JOURNAL OF FUNCTIONAL BIOMATERIALS, vol. 3, no. 1, doi:10.3390/jfb3010079, (20120119), pages 79 - 99, URL: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4031017/pdf/jfb-03-00079.pdf, XP055880989 [X] 1,2,4-6,12-14,18,19,22,23,26,27 * figures 1-14 * * Section 3, staring on page 91 * [Y] 1-28 [I] 7-11,21,24,25,28

DOI:   http://dx.doi.org/10.3390/jfb3010079
 [XYI]  - YUAN YE ET AL, "A multiple drug loaded, functionalized pH-sensitive nanocarrier as therapeutic and epigenetic modulator for osteosarcoma", SCIENTIFIC REPORTS, vol. 10, no. 15497, doi:10.1038/s41598-020-72552-z, (20200923), pages 1 - 11, URL: https://www.nature.com/articles/s41598-020-72552-z.pdf, XP055857230 [X] 1,2,4-6,12,18,19,22,23,27,28 * abstract * * figures 1-15 * * Discussion, par. 1 * [Y] 1-28 [I] 7-11,13,21,24-26

DOI:   http://dx.doi.org/10.1038/s41598-020-72552-z
 [Y]  - AKOURY ELIE ET AL, "Anti-Tumor Effects of Low Dose Zoledronate on Lung Cancer-Induced Spine Metastasis", JOURNAL OF CLINICAL MEDICINE, (20190814), vol. 8, no. 8, doi:10.3390/jcm8081212, page 1212, XP055881159 [Y] 1-28 * abstract *

DOI:   http://dx.doi.org/10.3390/jcm8081212
 [Y]  - DEEPAK BUSHAN RAINA ET AL, "A Biphasic Calcium Sulphate/Hydroxyapatite Carrier Containing Bone Morphogenic Protein-2 and Zoledronic Acid Generates Bone", SCIENTIFIC REPORTS, (20160518), vol. 6, no. 1, doi:10.1038/srep26033, XP055457462 [Y] 1-28 * abstract * * page 10, "Materials" *

DOI:   http://dx.doi.org/10.1038/srep26033
ExaminationWO2019206677
    - LIU YANG ET AL, "Sustained and controlled delivery of doxorubicin from an in-situ setting biphasic hydroxyapatite carrier for local treatment of a highly proliferative human osteosarcoma", ACTA BIOMATERIALIA, ELSEVIER, AMSTERDAM, NL, vol. 131, doi:10.1016/J.ACTBIO.2021.07.016, ISSN 1742-7061, (20210713), pages 555 - 571, (20210713), XP086746921

DOI:   http://dx.doi.org/10.1016/j.actbio.2021.07.016
by applicant   - STEFAN WILHELM, Nature Reviews Materials
    - KINAM PARK, Journal of Controlled Release
The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.